Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arrowhead Pharmaceuticals
Biotech
Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with MASH.
Will Maddox
May 5, 2026 10:40am
Arrowhead takes aim at obesity with early gene silencing data
Jan 6, 2026 10:19am
Sarepta shares safety update on DM1 RNA med
Nov 24, 2025 4:00pm
Arrowhead sues Ionis over patent dispute for Tryngolza rival
Sep 11, 2025 11:33am
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
Sarepta sells 9M Arrowhead shares for $174M cash
Aug 13, 2025 5:44pm
